» Articles » PMID: 35407466

How Can We Enhance Adherence to Medications in Patients with Systemic Lupus Erythematosus? Results from a Qualitative Study

Overview
Journal J Clin Med
Specialty General Medicine
Date 2022 Apr 12
PMID 35407466
Authors
Affiliations
Soon will be listed here.
Abstract

Medication non-adherence is common among patients with systemic lupus erythematosus (SLE) and may lead to poor clinical outcomes. Our aim was to identify influenceable contributors to medication non-adherence and suggest interventions that could increase adherence. Patients with SLE from two Swedish tertiary referral centres ( = 205) participated in a survey assessing self-reported adherence to medications. Responses were used to select patients for qualitative interviews ( = 15). Verbatim interview transcripts were analysed by two researchers using content analysis methodology. The median age of the interviewees was 32 years, 87% were women, and their median SLE duration was nine years. Reasons for non-adherence were complex and multifaceted; we categorised them thematically into (i) patient-related (e.g., unintentional non-adherence due to forgetfulness or intentional non-adherence due to disbelief in medications); (ii) healthcare-related (e.g., untrustworthy relationship with the treating physician, authority fear, and poor information about the prescribed medications or the disease); (iii) medication-related (e.g., fear of side-effects); and (iv) disease-related reasons (e.g., lacking acceptance of a chronic illness or perceived disease quiescence). Interventions identified that healthcare could implement to improve patient adherence to medications included (i) increased communication between healthcare professionals and patients; (ii) patient education; (iii) accessible healthcare, preferably with the same personnel; (iv) well-coordinated transition from paediatric to adult care; (v) regularity in addressing adherence to medications; (vi) psychological support; and (vii) involvement of family members or people who are close to the patient.

Citing Articles

Holistic approaches in systemic lupus erythematosus: do physicians avoid addressing difficult-to-treat but highly relevant symptoms?.

Parodis I, Wincup C, Touma Z, Andersen J, Strand V, Sjowall C RMD Open. 2025; 11(1).

PMID: 40055003 PMC: 11891533. DOI: 10.1136/rmdopen-2024-005400.


Feasibility and Acceptability of a REDCap-Embedded HIPAA-Compliant Text Messaging Application to Track Medication Adherence in Adolescents With Lupus.

Harry O, Richard B, Taxter A, Skelton J J Clin Rheumatol. 2024; 30(8):332-335.

PMID: 39352307 PMC: 11747896. DOI: 10.1097/RHU.0000000000002142.


Evolving Concepts in Treat-to-Target Strategies for Systemic Lupus Erythematosus.

Nikolopoulos D, Lourenco M, Depascale R, Triantafyllias K, Parodis I Mediterr J Rheumatol. 2024; 35(Suppl 2):328-341.

PMID: 39193182 PMC: 11345603. DOI: 10.31138/mjr.290424.eci.


Collating the voice of people with autoimmune diseases: Methodology for the Third Phase of the COVAD Studies.

Kadam E, Javaid M, Sen P, Saha S, Ziade N, Day J Rheumatol Int. 2024; 44(7):1233-1244.

PMID: 38609655 PMC: 11178609. DOI: 10.1007/s00296-024-05562-z.


Factors Associated with Survival and Discontinuation of Anti-Malarial Agents in Systemic Lupus Erythematosus: Results from a Tertiary Swedish Referral Centre.

Walhelm T, Wirestam L, Enman Y, Parodis I, Sjowall C J Clin Med. 2024; 13(5).

PMID: 38592294 PMC: 10934232. DOI: 10.3390/jcm13051485.


References
1.
Wohlfahrt A, Campos A, Iversen M, Gagne J, Massarotti E, Solomon D . Use of rheumatology-specific patient navigators to understand and reduce barriers to medication adherence: Analysis of qualitative findings. PLoS One. 2018; 13(7):e0200886. PMC: 6053216. DOI: 10.1371/journal.pone.0200886. View

2.
Durcan L, Clarke W, Magder L, Petri M . Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. J Rheumatol. 2015; 42(11):2092-7. PMC: 4630115. DOI: 10.3899/jrheum.150379. View

3.
Zhang X, Tian Y, Li J, Zhao X . Effect of targeted nursing applied to SLE patients. Exp Ther Med. 2016; 11(6):2209-2212. PMC: 4887837. DOI: 10.3892/etm.2016.3173. View

4.
van Vollenhoven R, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrom K . Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014; 73(6):958-67. DOI: 10.1136/annrheumdis-2013-205139. View

5.
Gomez A, Soukka S, Johansson P, Akerstrom E, Emamikia S, Enman Y . Use of Antimalarial Agents is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus. J Clin Med. 2020; 9(6). PMC: 7355692. DOI: 10.3390/jcm9061813. View